Abstract:BACKGROUND:Randomized controlled trials are considered the gold standard for evaluating experimental treatments but often require large sample sizes. Single-arm trials require smaller sample sizes but are subject to bias when using historical control data for comparative inferences. This article presents a Bayesian adaptive synthetic-control design that exploits historical control data to create a hybrid of a single-arm trial and a randomized controlled trial.METHODS:The Bayesian adaptive synthetic control design has two stages. In stage 1, a prespecified number of patients are enrolled in a single arm given the experimental treatment. Based on the stage 1 data, applying propensity score matching and Bayesian posterior prediction methods, the usefulness of the historical control data for identifying a pseudo sample of matched synthetic-control patients for making comparative inferences is evaluated. If a sufficient number of synthetic controls can be identified, the single-arm trial is continued. If not, the trial is switched to a randomized controlled trial. The performance of The Bayesian adaptive synthetic control design is evaluated by computer simulation.RESULTS:The Bayesian adaptive synthetic control design achieves power and unbiasedness similar to a randomized controlled trial but on average requires a much smaller sample size, provided that the historical control data patients are sufficiently comparable to the trial patients so that a good number of matched controls can be identified in the historical control data. Compared to a single-arm trial, The Bayesian adaptive synthetic control design yields much higher power and much smaller bias.CONCLUSION:The Bayesian adaptive synthetic-control design provides a useful tool for exploiting historical control data to improve the efficiency of single-arm phase II clinical trials, while addressing the problem of bias when comparing trial results to historical control data. The proposed design achieves power similar to a randomized controlled trial but may require a substantially smaller sample size.

On Construction of Single-Arm Two-Stage Designs with Consideration of Both Response and Toxicity

Utpi: A Utility‐based Toxicity Probability Interval Design for Phase I/II Dose‐finding Trials

Comparative Review of Novel Model‐assisted Designs for Phase I Clinical Trials

An Adaptive Trial Design to Optimize Dose-Schedule Regimes with Delayed Outcomes

Bayesian Phase II Adaptive Randomization by Jointly Modeling Time-to-event Efficacy and Binary Toxicity

Adaptive designs for identifying optimal biological dose for molecularly targeted agents.

Two-phase designs with failure time processes subject to nonsusceptibility

Bayesian Optimal Phase II Design for Randomized Clinical Trials

Comparative review of novel model-assisted designs for phase I clinical trials.

Bayesian Dose Finding by Jointly Modelling Toxicity and Efficacy As Time-To-Event Outcomes

Bayesian Optimal Interval Design: A Simple and Well-Performing Design for Phase I Oncology Trials.

On the Relative Efficiency of Model-Assisted Designs: a Conditional Approach.

MT-Keyboard: A Bayesian Model-assisted Interval Design to Account for Toxicity Grades and Types for Phase I Trials

Time-to-event Model-Assisted Designs for Dose-Finding Trials with Delayed Toxicity

Keyboard: A Novel Bayesian Toxicity Probability Interval Design for Phase I Clinical Trials

BASIC: A Bayesian Adaptive Synthetic-Control Design for Phase II Clinical Trials.

Gboin: a Unified Model-Assisted Phase I Trial Design Accounting for Toxicity Grades, and Binary or Continuous End Points

TITE‐BOIN12: A Bayesian Phase I/II Trial Design to Find the Optimal Biological Dose with Late‐onset Toxicity and Efficacy

Phase I–II Clinical Trial Design: a State-of-the-art Paradigm for Dose Finding

A Bayesian Dose-Finding Design for Phase I/II Clinical Trials with Nonignorable Dropouts.

BOP2: Bayesian Optimal Design for Phase II Clinical Trials with Simple and Complex Endpoints.